Rectal Cancer Clinical Trial
Official title:
Outcomes of Transanal Minimally Invasive TME Versus Laparoscopic Intersphincteric Resection Techniques for Rectal Cancer After Initial Neoadjuvant Chemo-radiotherapy: Double Blinded Study
A prospective study is planned for management of low rectal cancer with the aim of sphincter preservation and improving the oncological outcome of the patients, through comparing of both approaches minimally invasive techniques including transanal total mesorectal excision and laparoscopic intersphincteric resection.
Ideal surgery for rectal cancer should not only obtain adequate radial and circumferential
margins, but also preserve normal sphincter function.In 1990, the results of a 'close shave'
at anterior resection were reported, suggesting that a resection margin of 1 cm or less
produced an oncological outcome similar to that of a resection margin greater than 1 cm.
Sphincter preservation presents several advantages; The lower risk of intraoperative rectal
perforation and positive circumferential margin than APR, the lower risk of damaging the
pelvic branches of the pelvic autonomic nerve and The preservation of the body image that
may increase quality of life.
Recently, the clinical outcome of intersphincteric resection (ISR) as a laparoscopic
approach (laparoscopic ISR) has been reported, but laparoscopic ISR for patients with bulky
low rectal cancer remains challenging particularly for T3 tumors in patients with a narrow
pelvis, because of the difficulty in understanding the accurate anatomy of the small pelvic
cavity, in dissecting the TME or the tumor specific mesorectal excision (TSME) plane, and in
transecting the lower rectum safely. Moreover, numerous studies have demonstrated that
laparoscopic techniques have many advantages in colorectal surgery compared with open
surgery.
Although Radical resection is the gold standard for the treatment of rectal cancer, TEM
offers the advantage of combining a minimally invasive technique with evident benefits in
terms of postoperative morbidity and recovery, long-term functional outcomes and
subsequently improved quality of life. Transanal Endoscopic Microsurgery (TEM) developed at
1984 and eliminated most of local transanal excision limitations and triggered a significant
improvement in the local excision procedures of rectal lesions. While TEM became the 'gold
standard' for the treatment of large rectal adenomas and early rectal cancer, there are
special concerns about the lack of adequate lymphadenectomy.
Preoperative chemoradiation therapy is widely used to treat locally advanced rectal cancer
to increase resectability, and to enhance sphincter preservation, local control and
possibly, survival rates. Surgery is performed six to eight weeks after radiotherapy.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |